Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Operating Expenses for 4 consecutive years, with $24.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 42.72% to $24.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.3 million through Dec 2025, up 27.41% year-over-year, with the annual reading at $85.3 million for FY2025, 27.41% up from the prior year.
  • Operating Expenses for Q4 2025 was $24.2 million at Orchestra BioMed Holdings, up from $21.2 million in the prior quarter.
  • The five-year high for Operating Expenses was $24.2 million in Q4 2025, with the low at $6.0 million in Q1 2022.
  • Average Operating Expenses over 4 years is $15.2 million, with a median of $15.0 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 112.03% in 2023, then grew 14.32% in 2025.
  • Over 4 years, Operating Expenses stood at $10.9 million in 2022, then grew by 16.58% to $12.7 million in 2023, then skyrocketed by 32.86% to $16.9 million in 2024, then skyrocketed by 42.72% to $24.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $24.2 million, $21.2 million, and $20.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.